PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc. (OAPI) and Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has expanded the label of ...

Data from Phase 3 Trial demonstrated improvement in time to relapse, the primary efficacy endpoint, for patients receiving once-monthly aripiprazole IM depot formulation compared to placebo Results ...

Abilify Asimtufii (aripiprazole) is prescribed to help treat schizophrenia and bipolar I disorder. The drug comes as a suspension (a liquid mixture) that a healthcare professional injects into a ...

Aristada (aripiprazole lauroxil) is a prescription drug that’s used to treat schizophrenia. Aristada is given by a healthcare professional as an injection into a muscle. Aristada is used as a ...

On Monday, May 7, during a poster session at the 2018 Annual Meeting of the American Psychiatric Association, researchers presented new data on the injectable antipsychotic treatment aripiprazole ...

According to the National Institute on Minority Health and Health Disparities (NIMHD), less than half of all Americans who have a mental disorder get proper treatment, and less than 10% of patients ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational ...

TOKYO, JAPAN & PRINCETON, NEW JERSEY, FEBRUARY 29 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a new drug application for a treatment for schizophrenia or bipolar I disorder. The injectable ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration (FDA) ...

NEW YORK CITY -- An investigational 1-day aripiprazole initiation regimen was comparable in efficacy to usual treatment, according to a phase I study presented here. For the treatment of schizophrenia ...

The first and only available dopamine partial agonist, ABILIFY is indicated for the short- and long-term treatment of schizophrenia including maintaining stability in adults who had been ...